Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

GlaxoSmithKline PLC Regulatory Filings 2012

May 3, 2012

5262_ffr_2012-05-03_5825d04c-7137-4700-b65c-3d78ecaccb61.zip

Regulatory Filings

Open in viewer

Opens in your device viewer

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For period ending May 2012

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or

will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the

information contained in this Form is also thereby furnishing the

information to the Commission pursuant to Rule 12g3-2(b) under the

Securities Exchange Act of 1934.

Yes No x

--

GlaxoSmithKline plc - Result of AGM

GlaxoSmithKline plc (GSK) announces that at its Annual General Meeting (AGM) today, all resolutions were passed by shareholders.

GlaxoSmithKline AGM Poll Results

The following table shows the votes cast for each resolution:

Resolution Total votes for * % Total votes against % Total votes cast Votes withheld **
1 Adoption of Directors' Report and Financial Statements 3,827,705,365 98.70 50,361,254 1.30 3,878,066,619 3,315,549
2 Approval of the Remuneration Report 3,641,744,377 95.70 163,812,052 4.30 3,805,556,429 75,828,261
3 Re-election of Sir Christopher Gent 3,757,599,321 96.90 120,406,731 3.10 3,878,006,052 3,377,349
4 Re-election of Sir Andrew Witty 3,874,304,280 99.90 3,878,779 0.10 3,878,183,059 3,214,858
5 Re-election of Professor Sir Roy Anderson 3,874,110,361 99.90 3,788,474 0.10 3,877,898,835 3,482,154
6 Re-election of Dr Stephanie Burns 3,874,188,220 99.90 3,706,042 0.10 3,877,894,262 3,485,110
7 Re-election of Stacey Cartwright 3,871,534,437 99.84 6,292,248 0.16 3,877,826,685 3,552,308
8 Re-election of Larry Culp 3,863,938,369 99.65 13,752,888 0.35 3,877,691,257 3,689,401
9 Re-election of Sir Crispin Davis 3,872,742,523 99.87 5,082,798 0.13 3,877,825,321 3,554,050
10 Re-election of Simon Dingemans 3,873,781,085 99.90 3,931,792 0.10 3,877,712,877 3,666,495
11 Re-election of Judy Lewent 3,871,977,307 99.85 5,954,264 0.15 3,877,931,571 3,447,684
12 Re-election of Sir Deryck Maughan 3,865,657,282 99.69 12,144,052 0.31 3,877,801,334 3,578,315
13 Re-election of Dr Daniel Podolsky 3,867,010,327 99.72 10,760,012 0.28 3,877,770,339 3,608,654
14 Re-election of Dr Moncef Slaoui 3,873,750,729 99.89 4,223,699 0.11 3,877,974,428 3,406,260
15 Re-election of Tom de Swaan 3,798,800,827 97.96 78,991,586 2.04 3,877,792,413 3,586,579
16 Re-election of Sir Robert Wilson 3,873,643,265 99.89 4,247,312 0.11 3,877,890,577 3,489,128
17 Re-appointment of auditors 3,796,598,526 99.27 27,986,430 0.73 3,824,584,956 56,794,117
18 Remuneration of auditors 3,843,027,589 99.46 20,772,856 0.54 3,863,800,445 17,579,487
19 Authority for the company to make donations to political organisations and incur political expenditure 3,806,217,378 98.23 68,562,707 1.77 3,874,780,085 6,605,082
20 Authority to allot shares 3,773,307,135 97.35 102,769,873 2.65 3,876,077,008 5,304,590
21 Disapplication of pre-emption rights *** 3,833,012,357 98.94 40,945,524 1.06 3,873,957,881 7,422,017
22 Authority for the company to purchase its own shares *** 3,860,354,462 99.55 17,589,398 0.45 3,877,943,860 3,443,301
23 Exemption from statement of senior statutory auditor's name 3,852,410,960 99.51 18,979,169 0.49 3,871,390,129 9,991,468
24 Authorise reduced notice of a general meeting other than an AGM *** 3,521,062,642 90.83 355,321,668 9.17 3,876,384,310 4,998,426
25 Renew the GSK ShareSave Plan 3,791,116,168 97.83 83,969,018 2.17 3,875,085,186 6,344,467
26 Renew the GSK ShareReward Plan 3,832,667,502 98.91 42,189,238 1.09 3,874,856,740 6,574,197

Notes:

  • Includes discretionary votes.

** A vote withheld is not a vote in law and is not counted in the calculation of the proportion of votes "For" or "Against" a resolution.

*** Indicates Special Resolutions requiring a 75% majority.

James Murdoch did not stand for re-election as a Director, and has stepped down from the Board with effect from noon today.

The following table provides further relevant information:

GlaxoSmithKline's Twelfth AGM (2012) GlaxoSmithKline's Eleventh AGM (2011)
Issued share capital (excluding Treasury Shares) 5,046,404,827 5,163,907,153
Total votes cast and votes withheld lodged as a % of GSK's issued share capital (excluding Treasury Shares) 76.91% 74.72%
Total shareholder population 147,408 155,990
Total number of proxies lodged 9,717 9,886
% of shareholders who lodged proxies 6.59% 6.34%
Number of shareholders, corporate representatives and proxies who attended the AGM 426 364

V A Whyte

Company Secretary

3 May 2012

These results will shortly be available on the company's website at www.gsk.com .

GlaxoSmithKline Enquiries: — UK Media enquiries: David Mawdsley +44 (0) 20 8047 5502 (London)
Stephen Rea +44 (0) 20 8047 5502 (London)
Sarah Spencer +44 (0) 20 8047 5502 (London)
David Daley +44 (0) 20 8047 5502 (London)
US Media enquiries: Kevin Colgan +1 919 483 2839 (North Carolina)
Melinda Stubbee +1 919 483 2839 (North Carolina)
Sarah Alspach +1 919 483 2839 (Washington, DC)
Jennifer Armstrong +1 919 483 2839 (Philadelphia)
Analyst/Investor enquiries: Sally Ferguson +44 (0) 20 8047 5543 (London)
Tom Curry + 1 215 751 5419 (Philadelphia)
Gary Davies + 44 (0) 20 8047 5503 (London)
Jeff McLaughlin + 1 215 751 7002 (Philadelphia)
Ziba Shamsi + 44 (0) 20 8047 3289 (London)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc

(Registrant)

Date: May 03, 2012

By: VICTORIA WHYTE


Victoria Whyte

Authorised Signatory for and on

behalf of GlaxoSmithKline plc